JG
XERS icon

Jefferies Group’s Xeris Biopharma Holdings XERS Stock Holding History

Jefferies Group’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-91,800
Closed -$244K – 1582
2020
Q2 		$244K Buy
+91,800
New +$320K ﹤0.01% 1047
2019
Q4 		– Sell
-11,698
Closed -$115K – 3060
2019
Q3 		$115K Buy
+11,698
New +$131K ﹤0.01% 2481

Other funds holding XERS

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Group's XERS Position: Q3 2020 in Review

Jefferies Group sold out of Xeris Biopharma Holdings (XERS) in Q3 2020, closing a stake of 91,800 shares — an estimated $244K sold.

Jefferies Group first reported a position in XERS in Q3 2019 and held it in 2 quarters. The position peaked at $244K in Q2 2020. 86 funds tracked by Wall St. Rank hold XERS as of Q3 2020.

  • Jefferies Group reported no remaining Xeris Biopharma Holdings position as of Q3 2020 after selling out during the quarter.
  • Jefferies Group sold 91,800 Xeris Biopharma Holdings shares in Q3 2020, an estimated $244K.
  • Jefferies Group first reported a position in Xeris Biopharma Holdings in Q3 2019 and held it in 2 quarters.
  • Jefferies Group's Xeris Biopharma Holdings position peaked at $244K in Q2 2020.
  • 86 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.